Three New Clinical Trials Available at Texas Retina
Medical researchers continue to make significant advances in the diagnosis and treatment of retinal conditions, and our physicians remain committed to participating in clinical trials that will improve care for our patients.
read more
New Treatment for Wet AMD and Diabetic Eye Disease Reduces Treatment Burden for Patients by Extending Dosing Intervals
On August 18, 2023, the U.S. Food and Drug Administration (FDA) approved Eylea HD (aflibercept), a high-dose version of Eylea, for the treatment of several retinal conditions, including advanced neovascular age-related macular
read more New Clinical Trials Available at Texas Retina
Our physicians remain committed to participating in ongoing retina research, providing our patients with access to promising new treatments through clinical trials. In fact, our research program has grown to become one
read more
Dr. Abbey Presents Phase 1 DAVIO Clinical Trial Results to the Association for Research in Vision and Ophthalmology
Dr. Abbey presented the results from the Phase 1 DAVIO trial at ARVO 2023, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The trial was a first-in-human
read more
Dr. Abbey Contributes to Real-world Study of Faricimab for Neovascular Age-related Macular Degeneration
The TRUCKEE study is a real-world, collaborative effort to investigate the efficacy, durability, and safety of a monoclonal antibody treatment called faricimab in patients suffering from neovascular age-related macular degeneration (nAMD) in
read more